This week’s biotechnology news headlines include, new report on industry shows R&D productivity, drug patent protection strains trade talks, GSK will roll out malaria vaccine, stem cell grant to UC Davis, Astrazeneca expands work with Isis pharma, new Opdivo combination, and Pfizer gets EU ok for Hospira buy.

Cell Culture Events

Workshops:

High Performance Tour 2015

Discover how to improve efficiency and productivity for your bioprocessing workflows during our exclusive High Performance Tour.

Learn how the choice of chromatography media (resins), hardware, and services can dramatically affect your process performance.

Register now to reserve your seat at this special event where you can gain insights in improved process efficiency and productivity.

Coming to these Cities:

• San Diego, CA – September 15, 2015
• San Francisco, CA – September 17, 2015

To Register – https://promo.gelifesciences.com/na/K15104/landing.html

Conferences:

September

• Stem Cells Regenerative Medicine Conference – September 2-3, 2015 – Mandarin Oriental, Washington D.C. – http://www.terrapinn.com/conference/stem-cells-and-regenerative-medicine-congress/#stem-cells-and-regenerative-medicine-congress Join 300+ attendees from stem cell, regenerative medicine, cell & Gene Therapy biotechs to discuss the hottest industry topics and make new connections. At this year’s event the regenerative medicine industry is taking it to the next level and discussing how genomics is changing the field – and highlighting the commercialization and manufacturing stories that have helped spur the recent success.Discover the future of the regenerative medicine industry with exclusive content.Co-located with:
• Cord Blood World – September 2-3, 2015 – Mandarin Oriental, Washington D.C. http://www.terrapinn.com/conference/stem-cells-and-regenerative-medicine-congress/C52334.stm

• Cell Therapy Bioprocessing – September 30 – October 2, 2015 – The Hilton Alexandria Mark Center, Alexandria, VA http://www.ibclifesciences.com/CellTherapy/overview.xml

October

• Bioproduction – October 14-15, 2015 – Dublin, Ireland – http://www.informa-ls.com/event/bio-production14Benchmark technological developments and explore best practices in biomanufacturingThe biopharmaceutical industry is making a capital investment of approximately $8 billion in new facilities in Ireland, most of which has come in the last 10 years, representing close to the biggest wave of investment in new biotech facilities anywhere in the world.Join us at BioProduction 2015 in Dublin this October to see why so much is being invested in this area and to network with leading players within this growing industry!BioProduction 2015: Europe’s leading and largest event for a comprehensive update on all aspects of large scale biological manufacturing. Providing insights on the latest technologies, upstream/downstream processing, process analytics, the implementation of continuous manufacturing, facility design, flexibility facilities and single use systems to reduce inefficiencies during the biomanufacturing process.4 Conferences – 1 Exhibition – 1 Congress
  • Conference 1: Continuous Manufacturing
  • Conference 2: Upstream Processing – Production, Development & Analytics
  • Conference 3: Manufacturing Strategy & Technology
  • Conference 4: Downstream Processing

  For more information on the 2015 event please visit the event website at http://www.informa-ls.com/CQ3531BioproductionCellEL

• Bioprocessing International – October 26-29, 2015 Hynes Convention Center Boston, MAhttp://www.ibclifesciences.com/BPI/overview.xml

Headlines

“New analysis underscores improving pharma R&D productivity,” Reuters

“Drug industry productivity is continuing to improve, with a bumper haul of new products being launched and companies proving more successful in the final stages of clinical testing, according to a new analysis.”

If you like this story, please see our blog titled “New Report Forecasts Sustained Growth in the Pharmaceutical Market through 2020”

“Patent Protection for Drugs Puts Pressure on U.S. in Trade Talks,” The New York Times

“With 12 nations pressing to conclude the largest regional trade accord ever, United States officials find themselves squeezed between activists pressing to secure access to low-cost pharmaceuticals and Republicans who say Congress will reject a deal without strong patent protections for the drug industry.”

If you like this story, please see our blog titled “Cancer Drug Market Continues to Grow and is Fueled by Significant R&D Focus and Clinical Pipeline”

“GlaxoSmithKline sees staged roll-out of malaria vaccine,” Reuters

“The world’s first malaria vaccine, which won a green light last week from European drugs regulators, will be rolled out gradually in Africa, its maker said on Wednesday.”

If you like this story, please see our blog titled “The Evolution of Vaccine Manufacturing – Past, Current, and Future Trends”

“UC Davis gets $8.5M for stem-cell research to help AIDS patients,” Sacramento Business Journal

“The California stem cell agency has approved a $8.5 million grant to researchers at UC Davis who are working on treatments for HIV/AIDS patients who have lymphoma.”

If you like this story, please see our blog titled “Culturing hPSCs: From MEFs to Naïve State Cells”

“Astrazeneca Expands Work With Isis to Use Genes to Fix Diseases,” Bloomberg Business

“AstraZeneca Plc and Isis Pharmaceuticals Inc. will work together, expanding an earlier collaboration, to seek Gene Therapy treatments for diseases affecting the heart, kidneys and the body’s metabolism.”

If you like this story, please see our blog titled “Cord Blood-derived HSCs – The Quest to Overcome Limited Cell Numbers”

“BMS in new Opdivo combo collaboration,” PharmaTimes

“Bristol-Myers Squibb is teaming up with Japanese firm Kyowa Hakko Kirin to test a combination of two of the firms’ immunotherapies.”

If you like this story, please see our blog titled “Cell Culture Media Optimization: Making the perfect magical potion”

“Pfizer wins EU approval for $15 billion Hospira buy,” Reuters

“U.S. drugmaker Pfizer (PFE.N) gained European Union antitrust approval on Tuesday for its proposed $15 billion acquisition of U.S. rival Hospira (HSP.N) after pledging to sell some drugs to allay competition concerns.”

If you like this story, please see our blog titled “3D Printing and 3D Bioprinting – Changing the Healthcare Landscape”